KAI Pharmaceuticals discovers and develops novel therapeutics for cardiovascular diseases, kidney diseases and pain.
Business Model: Non-Profit
Revenue: $0
Employees: 10,001-1
KAI Pharmaceuticals was acquired by
Amgen.
The acquisition happend on 2012-04-10.
Details of the transaction were not public
Address:
City: South San Francisco
State: California
Zip:
Country: United States
KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2006 | Series B | 7 | $35M |
Aberdare Ventures Delphi Ventures Intersouth Partners InterWest Partners Investor Growth Capital Limited MDS Capital Skyline Ventures Aberdare Ventures Delphi Ventures Intersouth Partners InterWest Partners Investor Growth Capital Limited MDS Capital Skyline Ventures |
12/2003 | Series A | 4 | $17M |
Intersouth Partners Skyline Ventures InterWest Partners Skyline Ventures Delphi Ventures Intersouth Partners Skyline Ventures InterWest Partners Skyline Ventures |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|